Pharmacokinetics and testosterone suppression of a single dose of polyestradiol phosphate (Estradurin®) in prostatic cancer patients

✍ Scribed by Stege, Reinhard; Gunnarsson, Per Olov; Johansson, Carl-Johan; Olsson, Per; Pousette, Åke; Carlström, Kjell

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 363 KB
• Volume: 28
• Category: Article
• ISSN: 0270-4137
• DOI: 10.1002/(sici)1097-0045(199605)28:5<307::aid-pros6>3.0.co;2-8

✦ Synopsis

The pharmacokinetics and endocrine effects of polyestradiol phosphate (PEP; EstradurinQD) were studied by determination of the concentrations of estradiol (EJ, unconjugated (El) and total estrone (tE,; 285% estrone sulfate), and testosterone in serum from 11 prostatic cancer patients after administration of a single intramuscular injection ( 320After injection of PEP, serum concentrations of E, , El, and tEl increased during 2-3 weeks. Thereafter serum E, declined monophasically with a mean half-life of 70 days. The elimination of El and tEl seemed to be governed by the formation of E,. The testosterone concentration decreased inversely to the raising E, level and reached castration levels within 3 weeks and remained at this level for about 2 weeks, whereafter it increased inversely to the decreasing E, concentrations.